Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-05-10
2005-05-10
Solola, Taofiq (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S465000
Reexamination Certificate
active
06890947
ABSTRACT:
Compounds of formula I are providedas well as pharmaceutically acceptable salts and esters thereof, wherein R1to R8, A, A1and n have the significance indicated in the specification.
REFERENCES:
patent: 4011326 (1977-03-01), Jensen
patent: 4598089 (1986-07-01), Hadvary et al.
patent: 5089514 (1992-02-01), Hulin
patent: 5599826 (1997-02-01), Mertens et al.
patent: 5811439 (1998-09-01), Ogawa et al.
patent: 5856529 (1999-01-01), Catt et al.
patent: 6004996 (1999-12-01), Shah et al.
patent: 6069156 (2000-05-01), Oku et al.
patent: 6121397 (2000-09-01), MacLeod et al.
patent: 6291685 (2001-09-01), Junghans et al.
patent: 6441185 (2002-08-01), Kühnle et al.
patent: 185359 (1986-06-01), None
patent: 189577 (1986-08-01), None
patent: 443449 (1991-08-01), None
patent: 524495 (1993-01-01), None
patent: 0903343 (1999-03-01), None
patent: 1 078 923 (2001-02-01), None
patent: WO 9119702 (1991-12-01), None
patent: WO 9401420 (1994-01-01), None
patent: WO 9413650 (1994-06-01), None
patent: WO 9517394 (1995-06-01), None
patent: WO 96 26207 (1996-08-01), None
patent: WO 9725042 (1997-07-01), None
patent: WO 97 27857 (1997-08-01), None
patent: WO 9908501 (1999-02-01), None
patent: WO 9910339 (1999-03-01), None
patent: WO 00 08002 (2000-02-01), None
patent: WO 0009122 (2000-02-01), None
patent: WO 0009123 (2000-02-01), None
patent: WO 0100603 (2001-01-01), None
patent: WO 02 08188 (2002-01-01), None
patent: WO 02 16331 (2002-02-01), None
patent: WO 03004458 (2003-01-01), None
patent: WO 03 040114 (2003-05-01), None
patent: WO 03053976 (2003-07-01), None
Keller and Wahli: Trends Endocrin. Metab. (1993); 4:291-296.
MacDougald and Lane: Current Biology vol. 5 pp. 618-621 (1995).
Guerre-Millo, et. al.; J Biol Chem2000; 275: 16638-16642.
Balfour, et. al.; Drugs 57 (1999) 921-930.
Haigh et. al., Tetrahedron: Asymmetry, 10, pp. 1353-1367, 1999.
Gotteland et al., Synlett, 9 pp. 931-932 (1995).
Hulin et al., J. Med. Chem., 39, pp. 3897-3907 (1996).
Nicolaou et al., J. Am. Chem. Soc., 122, pp. 3830-3838 (2000).
Nichols et al., Anal. Biochem., 257, pp. 112-119 (1998).
Einsiedel et. al., Bioorg. Med. Chem. Lett., 10, pp. 2041-2044 (2000).
Goto et al., Chem. Pharm. Bull., 19, pp. 2050-2057 (1971).
Reichstein et al., Helvetica Chimica Acta, 16, pp. 121-129 (1933).
Diels et al., chem.. Ber., 48, pp. 897-905 (1915).
Wightman et al., J. Org. chem.., 43, pp. 2167-2170 (1978).
Musser et al., J. Med. Chem. 30, pp. 62-67 (1987).
Rahman et al., J. Chem. Soc. Perkin Trans. 1, 12, pp. 2973-1977 (1983).
Kelly et. al., J. Am. Chem. Soc., 110, pp. 6471-6480 (1988).
Kneen et al., Synthetic Communications, 16, pp. 1635-1640 (1986).
Kim et al., Can. J. Chem., 60, pp. 2093-2098 (1982).
Pàrkànyi et al., Monatsh. Chem., 123, pp. 637-645 (1992).
STN International ® CAPLUS Database, Accession No. 2000; 117035; Collins et al., WO 2000008002, abstract.
Malamas, MS et al, Eur. J. Med. Chem. vol. 36, No. 1 (2001) pp. 31-42.
Hulin, B. et al., Current Pharmaceutical Design, vol. 2 (1996) pp. 85-102.
Oplinger, et. al., ACS National Meeting, San Diego, Apr. 1-5, 2001, Poster 238, Division of Medicinal Chemistry, Section C.
Gustavsson, et. al., Chemical Abstracts, vol. 138, No. 106,504 (2003).
Oku, Teruo et, Database CA, Abstract XP002265626.
Henke B R et al, Bioorganic & Medicinal Chemistry Letters, vol. 9 (23) (Dec. 1999).
Binggeli Alfred
Grether Uwe
Hilpert Hans
Humm Roland
Iding Hans
Hoffmann-La Roche Inc.
Johnston George W.
Megerditchian Samuel H.
Solola Taofiq
Tramaloni Dennis P.
LandOfFree
Indolyl derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Indolyl derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Indolyl derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3411929